From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
Health state
Utility
Source
Progression-free survival from first-line treatment
0.764
LYM-3002 [24]
Progressed from first-line treatment
0.693
Progression-free survival from second-line treatment
Progressed from second-line treatment
0.45
Doorduijn, 2005 [34]